Skip to content

Study · Animal study (in vivo) · mouse · 2021

13 results

Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma.

Xia Y, Wei J, Zhao S, Guo B, Meng F, Klumperman B, Zhong Z

Journal of controlled release : official journal of the Controlled Release Society24 Jun 2021Cited by 34 (Europe PMC)

PMID34174350 (opens in a new tab)DOI10.1016/j.jconrel.2021.06.032 (opens in a new tab)PepBankPUB-34174350
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, systemic polymersomal LTX‑315 reached tumor accumulation of 4.8% ID/g.

    In plain wordsIn mice, systemic polymersomal LTX‑315 accumulated in tumors.

    Peptide
    LTX-315
    Outcome
    Direction not reportedTumor accumulation
    Study

    mousen: not reported in source

    B16F10 melanoma
    Outcome group
    Pharmacokinetics · Cancer
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Measurements

    Tumor accumulation
    4.8 % ID/g
    cRGD-CPs-L

    Source sentences

    Summary
    The systemic administration of cRGD-CPs-L gave a notable tumor accumulation of 4.8% ID/g and significant retardation of tumor growth.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, systemic polymersomal LTX‑315 significantly delayed tumor growth.

    In plain wordsIn mice, systemic polymersomal LTX‑315 delayed tumor growth.

    Peptide
    LTX-315
    Outcome
    DecreaseTumor growth
    Study

    mousen: not reported in source

    B16F10 melanoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    The systemic administration of cRGD-CPs-L gave a notable tumor accumulation of 4.8% ID/g and significant retardation of tumor growth.
  3. 03LabIn vitro (cells)Efficacy outcome

    In cells, polymersomal LTX‑315 strongly and selectively killed B16F10 cells versus L929 fibroblasts.

    In plain wordsIn cells, polymersomal LTX‑315 selectively killed melanoma cells compared with fibroblasts.

    Peptide
    LTX-315
    Outcome
    Direction not reportedSelective tumor cell killing
    Study

    n: not reported in source

    B16F10 cells and L929 fibroblasts
    Comparator
    L929 fibroblasts
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    strong and selective killing of B16F10 cells (versus L929 fibroblasts) in vitro
  4. 04LabIn vitro (cells)Mechanism

    In cells, polymersomal LTX‑315 produced immunogenic effects similar to free LTX‑315, as shown by danger molecule release.

    In plain wordsIn cells, polymersomal LTX‑315 produced immune-related effects similar to free LTX‑315.

    Peptide
    LTX-315
    Outcome
    Direction not reportedImmunogenic effects
    Study

    n: not reported in source

    B16F10 cells
    Comparator
    Free LTX-315
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    which provoked similar immunogenic effects to free LTX-315 as revealed by release of danger-associated molecular pattern molecules.

Studies that did not test the peptide alone9

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

  1. 05AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome

    In mice, polymersomal LTX‑315 with polymersomal CpG and anti-PD-1 cured two out of seven animals.

    In plain wordsIn mice, polymersomal LTX‑315 with CpG and anti-PD-1 cured two out of seven animals.

    Peptide
    LTX-315
    Outcome
    Direction not reportedTumor cure
    Study

    mousen = 7

    B16F10 melanoma
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    More interestingly, the treatment of B16F10 tumor-bearing mice was further boosted by co-administration of polymersomal CpG and anti-PD-1 antibody, in which two out of seven mice were cured as a result of strong immune response and long-term immune memory protection.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  2. 06AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In mice, polymersomal LTX‑315 with CpG and anti-PD-1 produced long-term immune memory protection.

    In plain wordsIn mice, polymersomal LTX‑315 with CpG and anti-PD-1 produced lasting immune memory protection.

    Peptide
    LTX-315
    Outcome
    Direction not reportedImmune memory protection
    Study

    mousen: not reported in source

    B16F10 melanoma
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    More interestingly, the treatment of B16F10 tumor-bearing mice was further boosted by co-administration of polymersomal CpG and anti-PD-1 antibody, in which two out of seven mice were cured as a result of strong immune response and long-term immune memory protection.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  3. 07AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In mice, the LTX‑315, CpG and anti-PD-1 regimen showed IL-6 secretion.

    In plain wordsIn mice, the LTX‑315, CpG and anti-PD-1 regimen showed IL-6 secretion.

    Peptide
    LTX-315
    Outcome
    Direction not reportedIL-6 secretion
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    The immunotherapeutic effect was evidenced by secretion of IL-6, IFN-γ and TNF-α, tumor infiltration of CD8+ CTLs and Th, and induction of TEM and TCM in spleen.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  4. 08AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In mice, the LTX‑315, CpG and anti-PD-1 regimen showed IFN-γ secretion.

    In plain wordsIn mice, the LTX‑315, CpG and anti-PD-1 regimen showed IFN-γ secretion.

    Peptide
    LTX-315
    Outcome
    Direction not reportedIFN-γ secretion
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    The immunotherapeutic effect was evidenced by secretion of IL-6, IFN-γ and TNF-α, tumor infiltration of CD8+ CTLs and Th, and induction of TEM and TCM in spleen.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  5. 09AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In mice, the LTX‑315, CpG and anti-PD-1 regimen showed TNF-α secretion.

    In plain wordsIn mice, the LTX‑315, CpG and anti-PD-1 regimen showed TNF-α secretion.

    Peptide
    LTX-315
    Outcome
    Direction not reportedTNF-α secretion
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    The immunotherapeutic effect was evidenced by secretion of IL-6, IFN-γ and TNF-α, tumor infiltration of CD8+ CTLs and Th, and induction of TEM and TCM in spleen.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  6. 10AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In mice, the LTX‑315, CpG and anti-PD-1 regimen showed tumor infiltration by CD8+ CTLs.

    In plain wordsIn mice, the LTX‑315, CpG and anti-PD-1 regimen showed CD8+ immune cell entry into tumors.

    Peptide
    LTX-315
    Outcome
    Direction not reportedTumor CD8+ CTL infiltration
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    The immunotherapeutic effect was evidenced by secretion of IL-6, IFN-γ and TNF-α, tumor infiltration of CD8+ CTLs and Th, and induction of TEM and TCM in spleen.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  7. 11AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In mice, the LTX‑315, CpG and anti-PD-1 regimen showed tumor infiltration by Th cells.

    In plain wordsIn mice, the LTX‑315, CpG and anti-PD-1 regimen showed helper T-cell entry into tumors.

    Peptide
    LTX-315
    Outcome
    Direction not reportedTumor Th infiltration
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    The immunotherapeutic effect was evidenced by secretion of IL-6, IFN-γ and TNF-α, tumor infiltration of CD8+ CTLs and Th, and induction of TEM and TCM in spleen.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  8. 12AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In mice, the LTX‑315, CpG and anti-PD-1 regimen induced splenic TEM cells.

    In plain wordsIn mice, the LTX‑315, CpG and anti-PD-1 regimen induced TEM cells in the spleen.

    Peptide
    LTX-315
    Outcome
    IncreaseSplenic TEM induction
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    The immunotherapeutic effect was evidenced by secretion of IL-6, IFN-γ and TNF-α, tumor infiltration of CD8+ CTLs and Th, and induction of TEM and TCM in spleen.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  9. 13AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In mice, the LTX‑315, CpG and anti-PD-1 regimen induced splenic TCM cells.

    In plain wordsIn mice, the LTX‑315, CpG and anti-PD-1 regimen induced TCM cells in the spleen.

    Peptide
    LTX-315
    Outcome
    IncreaseSplenic TCM induction
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    The immunotherapeutic effect was evidenced by secretion of IL-6, IFN-γ and TNF-α, tumor infiltration of CD8+ CTLs and Th, and induction of TEM and TCM in spleen.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.